Why Do Patients With Gout Not Take Allopurinol?

Objective. The objectives of this study were to examine the reasons patients give for nonadherence to allopurinol and to examine differences in intentional nonadherence for patients who did and did not achieve serum urate (SU) levels at treatment target. Methods. Sixty-nine men with gout attending rheumatology clinics, all prescribed allopurinol for >= 6 months, completed the Intentional Non-Adherence Scale (INAS). Differences in the types of intentional nonadherence were analyzed between those who did and did not achieve SU at treatment target (< 0.36 mmol/L, 6 mg/dL). Results. The most frequently endorsed reasons for not taking their urate-lowering therapies (ULT) were because participants wanted to lead a normal life (23%) or think of themselves as a healthy person again (20%). Patients also reported not taking allopurinol as a way of testing if they really needed it (22%). Participants with SU above target endorsed significantly more INAS items as reasons for not taking their medication, had more medicine-related concerns, and were more likely to give Testing treatment as a reason for nonadherence. Participants who were younger, single, and non-New Zealand European also endorsed more reasons for not taking their allopurinol. Conclusion. The major reasons behind the patient's decision not to take allopurinol relate to the desire to lead a normal life and the strategy of testing the treatment to see if they could reduce the dose without getting symptoms. These results provide some potentially modifiable targets for adherence interventions and some recommendations to clinicians about how to reframe ULT for patients in order to improve adherence.

Automated summary

The objective of this study was to examine the reasons for nonadherence to allopurinol as reported by patients, and to compare intentional nonadherence between patients who achieved the target serum urate levels and those who did not. The results showed that the most commonly reported reasons for nonadherence were the desire to lead a normal life and the strategy of testing the treatment. Patients who did not achieve the target levels reported more concerns about the medication and were more likely to use testing as a reason for nonadherence.